Acute Myeloid Leukemia | Tumor

FDA Lifts Partial Hold on Trial Assessing Novel Therapy for Post-Transplant Acute Myeloid Leukemia

January 10th 2021, 3:00pm


The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.

CURE’s Clinical Trial Corner: December 2020

December 31st 2020, 2:00pm


Here is a list of some recent trials that launched within the cancer space in December.

The Top 10 FDA Oncology Drug Approvals of 2020

December 29th 2020, 2:00pm


Here are the top 10 FDA oncology drug approvals that you may have missed this year.

The Top 5 News and Updates in Acute Myeloid Leukemia That Patients May Have Missed in 2020

December 26th 2020, 3:00pm


A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.

Understanding Treatment Options for Acute Myeloid Leukemia

December 24th 2020, 4:00pm


In this episode of the “CURE Talks Cancer” podcast, Dr. Dan Pollyea discusses the basics of AML, as well as treatment options currently available for patients.

EDUCATED PATIENT® Acute Myeloid Leukemia Webinar: December 17, 2020

December 18th 2020, 1:00am


Watch our Acute Myeloid Leukemia Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

CURE’s Clinical Trial Corner: November 2020

November 26th 2020, 2:00pm


Here is a list of some recent trials that launched within the cancer space in November.

FDA Grants Regular Approval to Venclexta Combo for Untreated Acute Myeloid Leukemia

October 16th 2020, 6:20pm


After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.

Adding Venclexta to Chemotherapy Improves Survival in Some with AML Who Are Ineligible for Standard Treatment

September 10th 2020, 1:00pm


Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.

FDA Approves Onureg for Continued Treatment of Adults with AML Who Achieved First Complete Remission

September 1st 2020, 5:45pm


The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival of 24.7 months compared to 14.8 months for those who received placebo.